At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 444 enrolled
Drug / intervention
CB-839 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
In Brief
A Phase 2 clinical trial evaluating CB-839, Cabozantinib, and 1 other intervention for Advanced Renal Cell Carcinoma and Metastatic Renal Cell Carcinoma. Completed, enrolled 444 participants across 133 sites in 8 countries.
Detailed Summary
Tthe primary objective of this study is to compare blinded Independent Radiology Committee (IRC)-adjudicated progression free survival (PFS) of patients treated with CB-839 + cabozantinib (CB-Cabo) versus placebo + cabozantinib (Pbo-Cabo) for advanced or metastatic clear-cell RCC (ccRCC).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesAustralia, France, Germany, Italy, New Zealand, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedFeb 2018
Enrollment StartApr 2018
Primary CompletionAug 2020
Study CompletionJul 2021
TodayJul 2026
First PostedFeb 9, 2018
Enrollment StartApr 24, 2018
Primary CompletionAug 31, 2020
Study CompletionJul 16, 2021
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 8.4 years ago
Interventions
CB-839drug
Oral glutaminase inhibitor
Cabozantinibdrug
Oral receptor tyrosine kinase inhibitor
Placebodrug
Placebo tablets